PEAK6 Investments’s Aspire Biopharma ASBP Stock Holding History

PEAK6 Investments’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21	Closed	-$254K	–	5336
2022 Q3	$254K	Hold	21	–	–	﹤0.01%	3475
2022 Q2	$250K	Buy	+21	New	+$252K	﹤0.01%	4561

Other funds holding ASBP

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

PEAK6 Investments's ASBP Position: Q4 2022 in Review

PEAK6 Investments sold out of Aspire Biopharma (ASBP) in Q4 2022, closing a stake of 21 shares — an estimated $254K sold.

PEAK6 Investments first reported a position in ASBP in Q2 2022 and held it in 2 quarters. The position peaked at $254K in Q3 2022. 55 funds tracked by Wall St. Rank hold ASBP as of Q4 2022.

PEAK6 Investments reported no remaining Aspire Biopharma position as of Q4 2022 after selling out during the quarter.
PEAK6 Investments sold 21 Aspire Biopharma shares in Q4 2022, an estimated $254K.
PEAK6 Investments first reported a position in Aspire Biopharma in Q2 2022 and held it in 2 quarters.
PEAK6 Investments's Aspire Biopharma position peaked at $254K in Q3 2022.
55 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2022.

Based on PEAK6 Investments's 13F filing for Q4 2022, filed 10 Feb 2023.